What question did this study set out to answer?

This trial aims to assess the DASH diet's impact on cardiometabolic and atherogenic indices in individuals with metabolic syndrome.

February 27, 2026BMC Endocrine DisordersOpen Access

The effect of dietary approaches to stop hypertension (DASH) diet on cardiometabolic and atherogenic indices in subjects with metabolic syndrome: a randomized clinical trial

View Full Paper

Ask AI

Bookmark

This trial aims to assess the DASH diet's impact on cardiometabolic and atherogenic indices in individuals with metabolic syndrome.
Randomized clinical trial design
Participants with metabolic syndrome
Intervention group following DASH diet vs. control group on a common healthy diet
Key outcomes included cardiometabolic index and atherogenic indices
Evaluated at baseline and end of study
Intervention group showed significant decrease in cardiometabolic index (CMI) compared to control group (−0.38 vs. −0.02, p = 0.001)
Significant reduction in atherogenic index of plasma (AIP) (−0.04 vs. 0.01, p = 0.001)
Decreased atherogenic coefficient (AC) in intervention group (−0.31 vs. 0.01, p = 0.04)
Reduction in Castelli risk index II (CRI-II) in intervention group (−0.30 vs. −0.03, p = 0.009)

No takes yet. Share an insight, caveat, or question.

A randomized clinical trial shows DASH diet reduces cardiometabolic and atherogenic indices in metabolic syndrome, indicating its health benefits.

Wei et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

A randomized clinical trial shows DASH diet reduces cardiometabolic and atherogenic indices in metabolic syndrome, indicating its health benefits.